Medasense Biometrics
About Medasense Biometrics
Medasense Biometrics is a medical device company that has developed the NOL® (Nociception Level Index) technology, an AI-driven platform for objective and continuous pain monitoring. This non-invasive technology quantifies a patient’s physiological response to pain by processing multiple physiological parameters, such as photoplethysmograph (PPG), galvanic skin response (GSR), and peripheral temperature, obtained from a finger probe. The AI algorithms convert this complex data into a real-time pain level index (NOL™) on a scale of 0 to 100, where a value between 0-25 represents an appropriately suppressed physiological response to noxious stimuli and indicates adequate analgesia.
The primary application of Medasense’s flagship product, the PMD-200™, is in critical care settings and operating rooms, particularly for non-communicating patients under general anesthesia. By providing objective pain assessment, the NOL technology aims to enable clinicians to personalize pain management, optimize analgesic titration, avoid overmedication, and improve patient outcomes, including reducing postoperative pain and opioid consumption. The company is also developing NOLedge™, an investigational cloud-based platform that leverages AI capabilities for pain prediction, stratification, and prevention strategies in clinic and home-based care. The PMD-200™ is distributed in Europe by Medtronic and is commercially available in Canada, Latin America, Israel, Australia, and the United Arab Emirates, with FDA marketing authorization granted in the U.S. in February 2023.
Focus Areas
Business Intelligence
| Key Investors | Sabadell Asabys (Asabys Partners), Baxter Ventures, Olive Tree Ventures, LGL Capital, Benslie International Ltd. |
| Partnerships | Medtronic (Europe, Israel), Nihon Kohden (Japan), Panakeia, LLC (US government institutions), Blink Device Company (grant), Jefferson Health (study collaboration) |
| Technology | Multi-parametric sensor platform, advanced AI algorithms, cloud-based analytics, photoplethysmography-based finger sensor, real-time bedside monitoring systems, interoperability with patient monitor platforms |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Medasense's NOL technology offers objective, real-time insights into a patient's nociceptive state, especially crucial during general anesthesia or in critical care where verbal communication is impossible. This allows for more precise and personalized analgesic titration, moving beyond traditional, less sensitive indicators like heart rate and blood pressure. Utilizing NOL can lead to a significant reduction in postoperative pain, decreased opioid consumption, and improved hemodynamic stability, ultimately enhancing patient safety and recovery. It provides a confident assessment of pain treatment adequacy, complementing clinical judgment and potentially leading to cost savings for healthcare systems by reducing complications. Medasense also provides educational resources through its 'Medasense Academy' to support clinicians in adopting and effectively using the technology.
The PMD-200u2122 monitor is designed for interoperability and currently enables connectivity with Philips and Mindray patient monitors. Medasense is actively pursuing further integration of its technology into existing patient monitoring platforms to expand its reach and streamline workflow in various care settings.
What the Web Says
Medasense Biometrics is an Israeli company that has developed the NOL (Nociception Level) index technology, which objectively quantifies a patient's physiological pain response. Their flagship product, the PMD-200, uses this technology in critical care settings to visualize pain response and personalize treatment, particularly for patients under anesthesia who cannot communicate their pain levels. The technology has received FDA marketing authorization and is being studied for its effectiveness in various surgical procedures, including spine surgery.
Overall: PositiveStrengths
- Objectively quantifies pain response, addressing a long-standing need in anesthesia.
- Reduces reported postoperative pain by 33%.
- Leads to 80% fewer hypotensive events and improved hemodynamic stability.
- Helps avoid over- and under-analgesia, leading to safer opioid dosing and reduced complications.
- Non-invasive, continuous, and simple to use.
- Potential for cost savings and better use of healthcare resources.
Limitations
- No readily available negative product reviews or employer reviews on the requested platforms (G2, Glassdoor, Capterra, Reddit).
- Limited information on company culture or employee experiences.
- The technology is adjunctive, meaning it's used in addition to clinical judgment, not as a standalone solution.
Based on reviews from: Medasense Website, Medical Product Outsourcing, Asabys Partners, The National Law Review
Last updated: 2026-07-18
Videos
News, demos, and interviews about Medasense Biometrics.
Videos load interactively. If none appear, search YouTube for Medasense Biometrics →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Medasense Biometrics.
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]
Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]
Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]
Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]
Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]